ARPP-19 Mediates Herceptin Resistance via Regulation of CD44 in Gastric Cancer

PURPOSE: As the first-line drug for treatment of HER2-positive metastatic gastric cancer (GC), Herceptin exhibits significant therapeutic efficacy. However, acquired resistance of Herceptin limits the therapeutic benefit of gastric cancer patients, in which the molecular mechanisms remain to be furt...

Descripción completa

Detalles Bibliográficos
Autores principales: Gao, Xiang, Lu, Changwen, Chen, Changyu, Sun, Kang, Liang, Qixin, Shuai, Jianfeng, Wang, Xiaoming, Xu, Yuxing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7354958/
https://www.ncbi.nlm.nih.gov/pubmed/32753897
http://dx.doi.org/10.2147/OTT.S253841

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7354958/
https://www.ncbi.nlm.nih.gov/pubmed/32753897
http://dx.doi.org/10.2147/OTT.S253841

Ejemplares similares